GlassScriptPhysician profile
Maya R Carter
NPI 1437294113
$29,005.68
in general payments reported to CMS, 2019-2025
81 companies · $3,507 in 2025
The $3,507 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,317 · 2020: $2,556 · 2021: $4,666 · 2022: $5,063 · 2023: $4,728 · 2024: $4,169 · 2025: $3,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,253.94 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,909.56 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Biogen, INC. | $2,720.06 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Teva Pharmaceuticals USA, INC. | $1,553.26 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Ucb, INC. | $1,479.38 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Pfizer INC. | $1,456.69 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,326.05 | 2019-2025 | |
| Lilly USA, LLC | $1,251.03 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Amgen INC. | $1,200.22 | 2019-2025 | Uplizna, Aimovig |
| Csl Behring | $853.21 | 2019-2025 | Hizentra |
| Genentech USA, INC. | $831.61 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Amneal Pharmaceuticals LLC | $704.14 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Allergan, INC. | $619.33 | 2019-2022 | |
| Lundbeck LLC | $593.64 | 2019-2025 | Vyepti |
| Eisai INC. | $593.25 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $583.11 | 2019-2025 | Ingrezza, Ongentys |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.